Blackrock Neurotech’s MoveAgain Brain-Computer Interface System Receives Breakthrough Device Designation from the FDA

SALT LAKE CITY, Nov. 16, 2021 /PRNewswire/ — Blackrock Neurotech, the leader in brain-computer interface technology, today announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its groundbreaking MoveAgain Brain Computer Interface (BCI) System. The first-of-its-kind system is expected to provide immobile patients the ability to control a mouse cursor, keyboard, mobile…

Read more